Parkinson’s disease is caused by the progressive death of dopamine-producing neurons in a small region of the brain called the substantia nigra. By the time the classic symptoms of tremor, stiffness, and slow movement appear, an estimated 35 to 80% of dopamine signaling in key movement-related brain areas has already been lost. The disease isn’t triggered by a single cause but by a collision of factors, including protein buildup inside neurons, energy failures in the cells’ power plants, immune reactions in the brain, genetic vulnerabilities, and environmental exposures.
Why Dopamine Neurons Are Uniquely Vulnerable
Not all brain cells are equally at risk in Parkinson’s. The neurons that die are concentrated in a specific part of the substantia nigra, while nearby dopamine neurons in an adjacent area are largely spared. The difference comes down to how these cells keep themselves firing.
Dopamine neurons in the substantia nigra use calcium channels to maintain their steady, rhythmic electrical activity. This calcium-driven pacemaking is metabolically expensive: the cells need enormous amounts of energy to pump calcium back out, which forces their mitochondria (the tiny power generators inside every cell) to work harder and produce more toxic byproducts called reactive oxygen species. Neighboring dopamine neurons that are spared in Parkinson’s rely instead on sodium channels for pacemaking, produce far less calcium stress, and carry higher levels of a protective calcium-buffering protein called calbindin.
Dopamine itself adds to the problem. It’s a chemically unstable molecule that spontaneously breaks down into toxic compounds called dopamine quinones and free radicals. When dopamine is properly packaged inside storage vesicles, it’s kept safely contained. But when those storage systems falter, loose dopamine in the cell reacts with iron (which is abundant in the substantia nigra) to generate even more damaging molecules. The very substance these neurons exist to produce becomes a source of internal chemical damage.
How Protein Clumps Destroy Cells From Within
A protein called alpha-synuclein is central to Parkinson’s. In healthy neurons, it exists in a soluble form and plays a role at the junctions where nerve cells communicate. In Parkinson’s, the balance between producing and clearing this protein breaks down. Alpha-synuclein misfolds, adopting an abnormal shape that causes copies of the protein to stick together into progressively larger clumps: first small clusters called oligomers, then longer chains called fibrils, and eventually dense masses known as Lewy bodies.
These protein aggregates collect in both the cell body and the long nerve fibers extending from it. They disrupt the cell’s normal dopamine signaling, interfere with the transport of essential materials along nerve fibers, and trigger inflammatory responses. The oligomers, the smaller early-stage clumps, appear to be especially toxic, damaging cell membranes and impairing the function of mitochondria before the larger Lewy bodies even form.
The Brain’s Immune System Turns Harmful
The brain has its own resident immune cells called microglia. In Parkinson’s, large numbers of these cells become activated in the substantia nigra, particularly in the areas where neuron loss is most severe. Once activated, microglia release hydrogen peroxide and nitric oxide, both of which are reactive molecules that damage dopamine neurons.
This creates a destructive feedback loop. Dying dopamine neurons release debris and abnormal proteins into the surrounding tissue, which activates more microglia, which release more toxic molecules, which kill more neurons. Research suggests this immune and inflammatory activity is tightly linked to the oxidative stress seen in Parkinson’s, with activated microglia amplifying and propagating the damage rather than simply responding to it. The inflammation may even initiate injury to neurons that were otherwise still functioning.
Mitochondrial Failure and Energy Crisis
Mitochondria convert nutrients into usable cellular energy. In Parkinson’s, a specific part of this energy-conversion chain, called complex I, is impaired. When complex I doesn’t work properly, two things happen: the cell can’t produce enough energy, and it generates excessive amounts of damaging free radicals.
This connection was first discovered through environmental toxins. Pesticides like rotenone and paraquat both inhibit complex I, and chronic exposure to rotenone reproduces many features of Parkinson’s in laboratory studies. Rotenone is notable because it specifically targets dopamine-producing cells even though it suppresses complex I function in all cell types, suggesting that dopamine neurons’ already-stressed mitochondria are operating with almost no safety margin.
When mitochondria fail in these neurons, they can no longer maintain proper calcium balance, leading to calcium flooding inside the cell. The neurons respond in the earliest stages by reducing their firing rate, essentially powering down to conserve energy. But this defensive shutdown can only delay the inevitable. Eventually the energy deficit, combined with the buildup of toxic byproducts, triggers cell death pathways.
Genetic Risk Factors
About 5 to 10% of Parkinson’s cases are directly inherited, with mutations identified in at least 20 genes. The two most influential are the LRRK2 gene and the SNCA gene (which encodes alpha-synuclein). More than 20 additional genetic risk locations have been identified through large-scale genome studies, meaning that even in “sporadic” cases with no family history, genetic susceptibility often plays a role.
Mutations in LRRK2 increase the activity of an enzyme that triggers cell death signaling pathways, impairs the cell’s ability to break down and recycle damaged proteins, promotes inflammatory responses, and causes oxidative damage. LRRK2 mutations also boost the production of alpha-synuclein, accelerating the protein-clumping process. What makes LRRK2 particularly significant is that its mutations contribute to both inherited and sporadic forms of the disease. Mutations in GBA, a gene involved in cellular waste processing, and PINK1, which helps maintain healthy mitochondria, round out the list of major genetic contributors.
Environmental Triggers
Pesticide exposure is the most established environmental risk factor. Rotenone (used as an insecticide and fish poison) and paraquat (an herbicide) both damage the mitochondrial energy chain in dopamine neurons. Rotenone is especially concerning because it specifically targets dopamine-producing cells while leaving other cell types relatively unharmed, even though it suppresses energy production in all of them.
The link between pesticide exposure and Parkinson’s was originally noticed in agricultural communities with higher rates of the disease. These chemicals likely interact with genetic susceptibility: someone carrying a LRRK2 or GBA mutation who is also chronically exposed to pesticides faces compounding risks, as their neurons have diminished defenses against the mitochondrial stress these chemicals cause.
How Dopamine Loss Creates Movement Problems
Dopamine from the substantia nigra feeds into a brain region called the striatum, which acts as a traffic controller for voluntary movement. The striatum manages two competing pathways: a “go” pathway that facilitates movement and a “stop” pathway that suppresses it. Dopamine normally tips the balance toward the “go” side.
When dopamine levels drop, the “stop” pathway becomes overactive. This chain reaction leads to excessive inhibition of the brain’s motor relay station (the thalamus), which reduces the signals reaching the motor cortex. The result is the hallmark motor symptoms: slowness of movement, muscle rigidity, and difficulty initiating actions like standing up from a chair or taking the first step when walking. Tremor at rest, the symptom most people associate with Parkinson’s, arises from abnormal rhythmic activity in this same circuit.
Symptoms That Appear Before Tremor
Because dopamine loss begins years before motor symptoms become obvious, the disease produces a range of earlier warning signs. Loss of smell (hyposmia) is one of the most reliable early markers. In imaging studies, people with reduced smell who also had constipation showed dopamine transporter deficits more than 40% of the time, a strong signal that the disease process was already underway.
Acting out dreams during sleep, a condition called REM sleep behavior disorder, is another significant early sign. In one study, 17 of 43 people diagnosed with this sleep disorder had abnormal dopamine imaging, and 6 of those 17 developed Parkinson’s within two to three years. Depression, anxiety, and constipation also emerge in the premotor phase, often years before anyone notices a tremor. These early symptoms reflect the fact that Parkinson’s doesn’t only destroy dopamine neurons. It also damages brain cells that produce serotonin and norepinephrine, neurotransmitters involved in mood regulation and gut function.
How Dopamine Replacement Works
The primary treatment for Parkinson’s compensates for the dopamine shortage rather than stopping the underlying cell death. Dopamine itself can’t cross from the bloodstream into the brain, so treatment uses levodopa, a precursor molecule that the brain can convert into dopamine. Levodopa is paired with a second drug (carbidopa) that blocks this conversion from happening outside the brain, ensuring more of the medication reaches the neurons that need it.
Once levodopa crosses into the brain, surviving dopamine neurons and other cells convert it into dopamine, which then activates the receptors that the dying neurons can no longer supply. This approach is effective at reducing motor symptoms, particularly in the earlier stages. Over time, as more neurons die and fewer cells remain to perform the conversion, the response to levodopa becomes less predictable, leading to fluctuations between periods of good symptom control and periods of stiffness or involuntary movements.
The Scale of the Problem
Parkinson’s is the second most common neurodegenerative disease after Alzheimer’s. Global prevalent cases grew from roughly 3.1 million in 1990 to nearly 11.8 million in 2021, a 2.7-fold increase. New diagnoses more than tripled over that same period, rising from about 417,000 to over 1.3 million per year. Men are affected at roughly 1.6 times the rate of women, with a global incidence of about 20 per 100,000 males compared to 12 per 100,000 females. Both figures are projected to continue climbing through at least 2026, driven by aging populations worldwide.